- GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 failCamlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.BioSpace · 7d ago↗ source
- BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsAnother biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…Fierce Biotech · 7d ago↗ source
- Insmed moves closer to $6B opportunity as PAH drug shows long-term durabilityInsmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements thro…